Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zentrela is a Canadian neurotechnology company that has developed a proprietary AI-based platform, the Cognalyzer, to objectively quantify the effects of cannabis and other psychoactive substances on the brain. By utilizing electroencephalogram (EEG) data and advanced machine learning algorithms, the company provides standardized Brainwaves-as-a-Service to help cannabis producers and pharmaceutical companies validate product claims and understand consumer experiences. Their technology addresses the lack of objective measurement tools in the rapidly growing cannabis and wellness markets, offering insights into onset time, potency, and duration of effects. Zentrela's research-backed approach aims to improve consumer safety and product transparency through data-driven neurological analysis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zentrela.